deucravacitinib
deucravacitinib: 21 clinical trials tracked.
deucravacitinib evidence translation
What we can confirm
21 tracked trials
What it means
What to watch
Prepared research question
What is verified about deucravacitinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 2 study sponsors
Clinical Trial Registry Records (21)showing 10 most recent
A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies
Primary endpoint: Number of participants treated
Deucravacitinib in the Treatment of Cicatricial Alopecias
Primary endpoint: Changes in IFNγ in CA scalp
Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease
Primary endpoint: Proportion of patients achieving a novel composite endpoint of BSA </= 1 AND SJC </= 1) OR (BSA </= 1 AND TJC </= 1) at 24 weeks
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
Primary endpoint: Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
Primary endpoint: Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization
A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis
Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16
The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy
Primary endpoint: Number of major congenital malformations among infants
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
Primary endpoint: Time to first flare during the withdrawal period
A Cohort Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis Using Administrative Health Claims Database
Primary endpoint: Participant baseline demographics
A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
Primary endpoint: Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score